Sign in →

Test Code HYPOG Hypoglycemic Agent Screen, Serum

Reporting Name

Hypoglycemic Agent Scrn, S

Useful For

Evaluation of suspected insulinoma characterized by hypoglycemia and increased plasma insulin concentration.

 

Detecting drugs that stimulate insulin secretion

 

If hypoglycemia is the result of 1 of these drugs, the test will detect the drug at physiologically significant concentrations in serum during an episode of hypoglycemia.

 

Drugs detected by this procedure are:

-The first-generation sulfonylureas-acetohexamide, chlorpropamide, tolazamide, and tolbutamide

-The second-generation sulfonylureas--glimepiride, glipizide, and glyburide

-The meglitinide-repaglinide

 

Drugs designed to make tissues more sensitive to insulin that do not induce hypoglycemia, such as pioglitazone, rosiglitazone, and troglitazone (recently withdrawn from the United States market) are not included in this screen test.

 

Drugs that lower blood glucose through mechanisms not related to stimulation of insulin secretion, such as acarbose, metformin, and miglitol are not included in this screen test.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum Red


Specimen Required


Collection Container/Tube: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 3 mL


Specimen Minimum Volume

1.1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Red Frozen (preferred) 14 days
  Ambient  14 days
  Refrigerated  14 days

Reference Values

ACETOHEXAMIDE

Negative: <1,000 ng/mL

 

CHLORPROPAMIDE

Negative: <1,000 ng/mL

 

TOLAZAMIDE

Negative: <20 ng/mL

 

TOLBUTAMIDE

Negative: <50 ng/mL

 

GLIMEPIRIDE

Negative: <20 ng/mL

 

GLIPIZIDE

Negative: <3 ng/mL

 

GLYBURIDE

Negative: <3 ng/mL

 

REPAGLINIDE

Negative: <3 ng/mL

Note: The report indicates a specific drug is positive if that drug is detected at a concentration greater than the sensitivity limit. The test sensitivity limit listed for each drug is lower than the concentration that will cause increased insulin and decreased glucose.

Day(s) and Time(s) Performed

Monday, Wednesday, Friday (9 a.m. cutoff)

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

80307

LOINC Code Information

Test ID Test Order Name Order LOINC Value
HYPOG Hypoglycemic Agent Scrn, S In Process

 

Result ID Test Result Name Result LOINC Value
21294 Acetohexamide 43626-1
21295 Chlorpropamide 48329-7
21296 Tolazamide 21566-5
21297 Tolbutamide 21567-3
21298 Glimepiride 48325-5
21299 Glipizide 48326-3
21300 Glyburide 48327-1
21301 Repaglinide 48328-9
21308 Comment 48767-8

Method Name

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Forms

If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.